About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company developing first-in-class therapies capable of rapidly regressing atherosclerotic plaque, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced they have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) mRNA technology with Genevant’s proprietary LNP technology in the development of a potential novel treatment for atherosclerosis.

“Our Cholesterol Degrading Platform enables us to produce therapies designed to reverse the progression of conditions such as atherosclerosis that are driven by localized accumulations of excess cholesterol in the body. Our first CDP mRNA therapy targets atherosclerosis and, as with all mRNA-based approaches, delivery is essential to achieving therapeutic benefit. We are excited to be working with Genevant, a recognized leader in the LNP space,” said Reason, Chief Executive Officer and co-founder of Repair.

“Successful development of mRNA and other nucleic acid-based therapies simply cannot happen without efficient delivery, and, with our longstanding leadership position in LNP technology, Genevant is well positioned to help innovative payload companies like Repair accomplish their objectives,” said James Heyes, Chief Scientific Officer of Genevant Sciences. “We are delighted to collaborate with Repair in the development of a potential new therapeutic option for atherosclerosis.”

Under the terms of the agreement, Genevant has granted to Repair a nonexclusive worldwide license to certain Genevant LNP technology to exploit CDP mRNA-LNP products for a specified field that includes atherosclerosis. Genevant is eligible to receive up to $107 million in upfront and contingent milestone payments per product and tiered royalties ranging from the mid to high single digits on future product sales.

About Repair Biotechnologies
Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. The company’s Cholesterol Degrading Platform (CDP) gives rise to first-in-class therapies aimed at reversing atherosclerosis, familial hypercholesterolemia, and other conditions in which excess or modified cholesterol drives pathology. Current therapies such as statins and PCKS9 inhibitors can successfully reduce serum LDL-cholesterol, but are not effective at regressing established atherosclerotic plaque. For more information, please visit www.repairbiotechnologies.com.

About Genevant Sciences
Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a robust and expansive lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. The Company’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Company’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit www.genevant.com.


Contact
Pete Zorn
pete.zorn@genevant.com

Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
+0.00 (0.00%)
AAPL  252.29
+0.00 (0.00%)
AMD  233.08
+0.00 (0.00%)
BAC  51.28
+0.00 (0.00%)
GOOG  253.79
+0.00 (0.00%)
META  716.91
+0.00 (0.00%)
MSFT  513.58
+0.00 (0.00%)
NVDA  183.16
-0.06 (-0.03%)
ORCL  291.31
+0.00 (0.00%)
TSLA  439.31
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.